Astellas shutters OSI and Perseid, lets 200 US staff go in R&D reorg
May 14, 2013
6:56 pm
It was a particularly grim Monday for 200 Astellas employees in the US, who were informed that they were being let go and it was their last day with the company.
AstraZeneca consolidates R&D, moves US commercial roles
AstraZeneca is cutting 650 jobs in the US, “primarily in R&D,” and consolidating its R&D operations at three “strategic R&D centers” in “bioscience clusters,” academic and industrial beehives where the company can tap into concentrations of talent and infrastructure.
Company news: Pfizer, Vertex and Poz
December 19, 2012
5:54 pm
Pfizer and at least two other pharmas are spreading pink slips instead of cheer
WebMD is laying off 14% of its workforce in hopes of saving $45 million to offset revenue losses from an ongoing advertising slump that’s plagued the portal throughout 2012.
Company news: AstraZeneca, Targacept
October 9, 2012
4:46 pm
AstraZeneca buys license to kidney drug; Targacept has another round of layoffs.
Company news: Merck, Novo Nordisk
October 4, 2012
4:34 pm
Merck slims down, Novo goes wide
Lundbeck, building “European commercial model of the future,” lays off 600
Pharmas shrank their US sales forces by 7% between 2010 and 2011, but the pain wasn’t shared evenly between the biggest of pharmas, as a number of players scaled up.
Enbrel reps risk layoff, as Pfizer calls early end to US selling
When Pfizer’s US Enbrel sales force gives way to Amgen’s in July, reps risk layoff if they don’t get picked up by Amgen or re-assigned to Pfizer’s new JAK inhibitor.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix